Incarnate Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 9 Year, 3 Days
- Last Filing with ROC 31 Mar 2018
- Revenue -30.89%
(FY 2018)
- Profit -54.36%
(FY 2018)
- Ebitda 29.09%
(FY 2018)
- Net Worth -170.71%
(FY 2018)
- Total Assets 9.36%
(FY 2018)
About Incarnate Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Dani and Neel Dani serve as directors at the Company.
- CIN/LLPIN
U24233GJ2016PTC085714
- Company No.
085714
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jan 2016
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Incarnate Pharmachem Private Limited offer?
Incarnate Pharmachem Private Limited offers a wide range of products and services, including Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Antibiotic Tablets & Capsules, Azithromycin Tablets, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Aceclofenac Tablet, Aceclofenac Paracetamol Tablet, Antibacterial Drugs, Ofloxacin Tablet IP.
Who are the key members and board of directors at Incarnate Pharmachem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neel Dani  | Additional Director | 08-Sep-2021 | Current |
| Sanjay Dani | Director | 13-Jan-2016 | Current |
Financial Performance of Incarnate Pharmachem.
Incarnate Pharmachem Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 30.89% decrease. The company also saw a substantial fall in profitability, with a 54.36% decrease in profit. The company's net worth observed a substantial decline by a decrease of 170.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Incarnate Pharmachem?
In 2018, Incarnate Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Incarnate Infrastructure Private LimitedActive 9 years 10 days
Sanjay Dani and Neel Dani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Incarnate Pharmachem?
Incarnate Pharmachem has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Incarnate Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Incarnate Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
